Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;28(4):373-379.
doi: 10.1111/resp.14409. Epub 2022 Nov 13.

Immunomodulatory treatment in unclassifiable interstitial lung disease: A retrospective study of treatment response

Charlotte Hyldgaard  1 , Sebastiano Torrisi  2   3 , Sissel Kronborg Brix-White  4 , Thomas Skovhus Prior  1   4 , Claudia Ganter  3 , Elisabeth Bendstrup  4   5 , Michael Kreuter  3
Affiliations
Free article

Immunomodulatory treatment in unclassifiable interstitial lung disease: A retrospective study of treatment response

Charlotte Hyldgaard et al. Respirology. 2023 Apr.
Free article

Abstract

Background and objective: The optimal management of unclassifiable Interstitial lung disease (ILD) remains a challenge. The aim of this study was to describe pulmonary function trajectories for patients treated with immunomodulatory therapy and for untreated patients.

Methods: Clinical information and treatment data were obtained retrospectively at two ILD centres. Pulmonary function data were analysed using (1) mixed effects linear regression models with and without clinical covariates and (2) propensity score matching using gender, age, physiology (GAP) stage, smoking and presence of ground glass opacities.

Results: Sixty-five percent of the 249 patients included received corticosteroids and/or other immunomodulators. Treated patients had lower forced vital capacity (FVC) (72% vs. 83% predicted) and diffusing capacity for carbon monoxide (DLco) (44% vs. 60% predicted). In mixed effects linear regression, the adjusted change in FVC was -0.22%, [-0.34; -0.11], and -0.15% [-0.28;-0.012] for DLco. The difference in pulmonary function decline between treated and untreated patients was insignificant, -0.082% per month, [-0.28; 0.11], p = 0.10 for FVC and -0.14% per month, [-0.36; 0.079], p = 0.15, for DLco. In propensity score matched analysis, the difference in change in FVC was 0.039% per month, p = 0.12, and for DLco, 0.0085% per month, p = 0.7.

Conclusion: The pulmonary function trajectories for treated and untreated patients were parallel, despite treated patients having more severe disease at baseline. The persisting differences between the groups suggest no overall effect, although improvement or stabilization may be seen in some patients. Prospective studies are needed to define subsets of patients with unclassifiable interstitial lung disease and their optimal management.

Keywords: immunomodulatory therapy; lung fibrosis; pulmonary function; rare lung disease; unclassifiable interstitial lung disease.

PubMed Disclaimer

References

REFERENCES

    1. Thomeer MJ, Vansteenkiste J, Verbeken EK, Demedts M. Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. Respir Med. 2004;98(6):567-73.
    1. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42(3):750-7.
    1. Hyldgaard C, Bendstrup E, Wells AU, Hilberg O. Unclassifiable interstitial lung diseases: clinical characteristics and survival. Respirology. 2017;22(3):494-500.
    1. Krauss E, El-Guelai M, Pons-Kuehnemann J, Dartsch RC, Tello S, Korfei M, et al. Clinical and functional characteristics of patients with unclassifiable interstitial lung disease (uILD): long-term follow-up data from European IPF Registry (eurIPFreg). J Clin Med. 2020;9(8):2499.
    1. Guler SA, Ellison K, Algamdi M, Collard HR, Ryerson CJ. Heterogeneity in unclassifiable interstitial lung disease. A systematic review and meta-analysis. Ann Am Thorac Soc. 2018;15(7):854-63.

Publication types

LinkOut - more resources